Pharmacological profile of the abeorphine 201–678, a potent orally active and long lasting dopamine agonist
- 13 January 1986
- journal article
- Published by Elsevier in Life Sciences
- Vol. 38 (2), 155-163
- https://doi.org/10.1016/0024-3205(86)90007-x
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Effects of (8β)-8-[(Methylthio)methyl]-6-propylergoline on dopaminergic function and brain dopamine turnover in ratsLife Sciences, 1979
- Comparison of the dopaminergic effects of apomorphine and (−)-N-n-propylnorapomorphineEuropean Journal of Pharmacology, 1978
- Lisuride Hydrogen Maleate: Evidence for a Long Lasting Dopaminergic Activity in HumansJournal of Clinical Endocrinology & Metabolism, 1978
- Hypokinesia produced by anterolateral hypothalamic 6-hydroxydopamine lesions and its reversal by some antiparkinson drugsPharmacology Biochemistry and Behavior, 1978
- Neurochemical and Neuropharmacological Investigations with Four Ergot Derivatives: Bromocriptine, Dihydroergotoxine, CF 25-397 and CM 29-712Pharmacology, 1978
- Treatment of Parkinson's Disease with AporphinesNew England Journal of Medicine, 1976
- STIMULANT PROPERTIES OF BROMOCRIPTINE ON CENTRAL DOPAMINE RECEPTORS IN COMPARISON TO APOMORPHINE, (+)‐AMPHETAMINE AND l‐DOPABritish Journal of Pharmacology, 1976
- Bromocriptine in ParkinsonismBMJ, 1974
- Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine systemBrain Research, 1970
- Similarities between Neurologic Effects of L-Dopa and of ApomorphineNew England Journal of Medicine, 1970